Karamanloğlu Beyhan, Turan Alparslan, Memiş Dilek, Türe Mevlüt
Department of *Anesthesiology and †Biostatistics, Trakya University, Medical Faculty, Edirne, Turkey.
Anesth Analg. 2004 Apr;98(4):1039-1043. doi: 10.1213/01.ANE.0000103295.31539.A7.
We designed this study to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia (PCA) tramadol use or enhance analgesia. Sixty patients were randomized to receive either oral placebo or rofecoxib 50 mg 1 h before surgery. All patients received a standard anesthetic protocol. Intraoperative blood loss was determined. At the end of surgery, all patients received tramadol IV via a PCA-device. Pain scores, sedation scores, mean arterial blood pressure, heart rate, and peripheral oxygen saturation were assessed at 1, 2, 4, 6, 8, 12, and 24 h after surgery. Total and incremental tramadol consumption at the same times was recorded from the PCA-device. Antiemetic requirements and adverse effects were noted during the first postoperative 24 h. Duration of hospital stay was also recorded. The pain scores were significantly lower in the rofecoxib group compared with the placebo group at 6 times during the first 12 postoperative h (P < 0.05). The total consumption of tramadol (627 +/- 69 mg versus 535 +/- 45 mg; P < 0.05) and the incremental doses at 1, 2, 4, 6, 8, and 12 h after surgery were significantly more in the placebo group than in the rofecoxib group. There were no differences between groups in intraoperative blood loss, sedation scores, hemodynamic variables, peripheral oxygen saturation, antiemetic requirements, or adverse effects after surgery. The length of hospital stay was also similar in the groups. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy.
This study was designed to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia tramadol use or enhance analgesia. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy.
我们开展这项研究，旨在确定对接受腹部子宫切除术的患者术前给予一剂罗非昔布，是否会减少患者自控镇痛（PCA）曲马多的使用量或增强镇痛效果。60例患者被随机分为两组，一组在术前1小时口服安慰剂，另一组口服50毫克罗非昔布。所有患者均接受标准麻醉方案。测定术中失血量。手术结束时，所有患者通过PCA装置静脉注射曲马多。在术后1、2、4、6、8、12和24小时评估疼痛评分、镇静评分、平均动脉血压、心率和外周血氧饱和度。从PCA装置记录同一时间的曲马多总消耗量和追加量。记录术后首24小时内的止吐需求和不良反应。记录住院时间。术后12小时内，罗非昔布组的疼痛评分在6个时间点均显著低于安慰剂组（P<0.05）。安慰剂组曲马多的总消耗量（627±69毫克对535±45毫克；P<0.05）以及术后1、2、4、6、8和12小时的追加剂量均显著高于罗非昔布组。两组在术中失血量、镇静评分、血流动力学变量、外周血氧饱和度、止吐需求或术后不良反应方面无差异。两组的住院时间也相似。我们得出结论，术前口服罗非昔布对接受腹部子宫切除术的患者具有显著的镇痛益处，并减少了阿片类药物的需求量。
本研究旨在确定对接受腹部子宫切除术的患者术前给予一剂罗非昔布，是否会减少患者自控镇痛曲马多的使用量或增强镇痛效果。我们得出结论，术前口服罗非昔布对接受腹部子宫切除术的患者具有显著的镇痛益处，并减少了阿片类药物的需求量。
